Intellia, Morgan Stanley
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Longer Term Trading Plans for NTLA. Buy NTLA near 10.06 target 13.33 stop loss @ 10.03 Details; The technical summary data ...
Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...
Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for future growth. Click for more on NTLA.
The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.
Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $9.42 which represents a decrease of $-0.29 or -2.99% from the prior close of $9.71. The stock opened at $9.76 and touched a low ...
Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on the shares. The discontinuation of the Alpha-1 Antitrypsin Deficiency ...
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of late-stage programs for NTLA-2002 and nex-z. These therapies target hereditary ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback